Trial Profile

A phase-II study of stereotactic body radiotherapy and sunitinib for patients with new metastatic renal cell carcinoma

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 14 Jul 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Sunitinib (Primary)
Indications Renal cell carcinoma
Focus Therapeutic Use

Most Recent Events

06 Jun 2023 Primary endpoint has been met (objective response rate) , according to results presented at the 59th Annual Meeting of the American Society of Clinical Oncology
06 Jun 2023 According to results presented at the 59th Annual Meeting of the American Society of Clinical Oncology, complete results are awaited in 2023 after follow-up completion of the entire cohort.
06 Jun 2023 Status changed to active, no longer recruiting, according to results presented at the 59th Annual Meeting of the American Society of Clinical Oncology

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com